Browsing Tag
Avacta Group plc
9 posts
Avacta Group (AIM: AVCT) claims preCISION payload delivery shows structural advantages over ADCs as AVA6103 nears clinic
Avacta Group plc releases new data claiming preCISION delivery advantages over ADCs as AVA6103 prepares to enter clinical trials. Read more.
Avacta (AIM: AVCT) sets 2026 clinical momentum with AVA6103 trial launch and AVA6000 data readouts
Avacta targets dual clinical milestones in 2026 with AVA6103 trial launch and AVA6000 readouts. Find out how its small-molecule platform could reshape oncology.
Can Avacta (AIM: AVCT) sustain momentum as AVA6103 data signals tumor-targeting breakthrough?
Avacta shares trade flat after releasing new AVA6103 data. Can the tumor-targeting strategy sustain momentum into Phase 1? Find out what traders expect.
Avacta Group PLC (AIM: AVCT) shares rise on dual payload breakthrough: Is a clinical re-rating next?
Avacta shares rise after unveiling dual payload cancer therapy at AACR-NCI-EORTC. Can the stock sustain momentum as it approaches clinical milestones?
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Avacta’s peptide drug conjugates could change how we deliver cancer drugs. Find out how they compare to ADCs and what’s next for the UK biotech’s platform.
Avacta completes Coris sale in final diagnostics exit: Is its precision oncology pivot ready for prime time?
Avacta completes sale of Coris Bioconcept to focus solely on oncology. Find out what this pivot means for its stock, strategy, and pre|CISION® pipeline.
Will Avacta’s pre|CISION platform turn its £3.25m bond repayment into a precision oncology breakthrough?
Avacta Group plc raises £3.25M to repay its convertible bond and extend clinical runway for its pre|CISION cancer drugs—find out what’s next.
Avacta Group advances Phase 1 trial of oncology drug candidate AVA6000
Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase…